Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1525

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 16
Chunk 1525
---
 (Predecessor) 
  
    Operating expenses: 

    Research and development 
    $6,315,552  
    $764,192  
    $5,288,580 
  
    General and administrative 
     8,985,351  
     132,941  
     2,386,469 
  
    Total operating expenses 
     15,300,903  
     897,133  
     7,675,049 
  
    Loss from operations 
     (15,300,903) 
     (897,133) 
     (7,675,049)

    Other income (expenses): 

    Gain from settlement of liabilities with vendors 
     3,339,223  
     -  
     8,144 
  
    Other expenses 
     (672,378) 
     -  
     (62,182)
  
    Change in fair value of earnout and derivative liabilities 
     4,880,000  
     320,117  
     301,170 
  
    Interest income, net 
     21,846  
     4,805  
     138,340 

    Total other income, net 
     7,568,691  
     324,922  
     385,472 

    Net loss 
     (7,732,212)
     (572,211) 
     (7,289,577)

    Deemed dividend - preferred stock conversions

    (2,508,000
    )

    -

    -

    Deemed dividend – warrant repricing

    (276,839
    )

    -

    -

    Net loss attributable to common shareholders 
     
    $
    (10,517,051
    )
     
    $
    (572,211
    )
     
    $
    (7,289,577
    )

    Net loss per common share: 

    Basic and diluted 
    $(18.15)
    $(97.90) 
    $(1,248.64)
  
    Weighted average common shares outstanding: 

    Basic and diluted 
     579,432 
     5,845  
     5,838 

See accompanying notes
to the consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8, 202